Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This study is testing whether combining two drugs, atezolizumab and derazantinib, can help control advanced bile duct cancer that has a specific genetic feature called an FGFR2 fusion. It is for adults who have had at most one prior treatment. The main goal is to see how many pat…

This study is testing if adding a new targeted drug, bemarituzumab, to standard chemotherapy can help control advanced stomach or gastroesophageal cancer that has worsened after initial treatment. It is for adults whose tumors have a specific marker (FGFR2b-positive). The main go…

This early-stage study is testing the safety and feasibility of new ways to deliver an immune-boosting drug called IMP321 to people with advanced solid tumors. Researchers are trying methods like injecting the drug directly into tumors or into the abdominal cavity, and combining …

This study aims to see if the drug brigatinib works better than other similar drugs for people with a specific type of advanced lung cancer (ALK-positive NSCLC). It will involve about 118 adults who have not yet received treatment for their advanced cancer. Researchers will close…

This study is testing whether combining two drugs, fedratinib and nivolumab, can help control myelofibrosis, a serious bone marrow cancer, in patients whose disease did not respond well to standard JAK-inhibitor therapy. It will involve about 30 adults with primary or secondary m…

This study is testing whether combining a type of radiation therapy with an immunotherapy drug (durvalumab) can help control stage III lung cancer in elderly or frail patients who are too weak for standard chemotherapy. The trial will enroll 51 patients to see if this combination…

This study is testing whether adding immunotherapy drugs to a standard targeted radiation treatment can better control advanced bile duct cancer that is confined to the liver. It will involve about 50 patients who have already tried standard chemotherapy. Patients will receive th…